Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11084)
All Articles published online
|
Publishing Process of This Article
|
Jan 7, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ezquer F, Bruna F, Calligaris S, Conget P, Ezquer M. Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease. World J Gastroenterol 2016; 22(1): 24-36 [PMID: 26755858 DOI: 10.3748/wjg.v22.i1.24] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v22/i1/24.htm |
| Number | Citing Articles |
| 1 |
Lichao Ge, Dazhi Chen, Wenkai Chen, Chao Cai, Ying Tao, Shasha Ye, Zhuo Lin, Xiaodong Wang, Ji Li, Lanman Xu, Yongping Chen. Pre-activation of TLR3 enhances the therapeutic effect of BMMSCs through regulation the intestinal HIF-2α signaling pathway and balance of NKB cells in experimental alcoholic liver injury. International Immunopharmacology 2019; 70: 477 doi: 10.1016/j.intimp.2019.02.021
|
| 2 |
Zerui Wang, Tiantian Li, Ziying Zhang, Mengqi Yuan, Ming Shi, Fu-Sheng Wang, En-Qiang Linghu, Lei Shi. Human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis (MSC-DLC-1): a dose-escalation, phase I trial protocol. BMJ Open 2023; 13(12): e078362 doi: 10.1136/bmjopen-2023-078362
|
| 3 |
Ling-Zu Kong, Nisansala Chandimali, Ying-Hao Han, Dong-Ho Lee, Ji-Su Kim, Sun-Uk Kim, Tae-Don Kim, Dong Kee Jeong, Hu-Nan Sun, Dong Sun Lee, Taeho Kwon. Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease. International Journal of Molecular Sciences 2019; 20(11): 2712 doi: 10.3390/ijms20112712
|
| 4 |
Irina Lyadova Vladimirovna, Ekaterina Sosunova, Alexander Nikolaev, Tatiana Nenasheva. Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation. Journal of Immunology Research 2016; 2016: 1 doi: 10.1155/2016/7121580
|
| 5 |
Szu-Yi Liu, I-Ting Tsai, Yin-Chou Hsu. Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives. International Journal of Molecular Sciences 2021; 22(10): 5170 doi: 10.3390/ijms22105170
|
| 6 |
Tilottama Parate, Pankaj Chavan, Ramesh Parate. A Clinical Study of Spectrum of Liver Diseases in Alcoholic with Respect to Predictors of Severity and Prognosis. Vidarbha Journal of Internal Medicine 2022; 32: 100 doi: 10.25259/VJIM_6_2021
|
| 7 |
Apeksha Damania, Deepika Jaiman, Arun Kumar Teotia, Ashok Kumar. Mesenchymal stromal cell-derived exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury. Stem Cell Research & Therapy 2018; 9(1) doi: 10.1186/s13287-017-0752-6
|
| 8 |
Jinsol Han, Chanbin Lee, Jin Hur, Youngmi Jung. Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease. Cells 2022; 12(1): 22 doi: 10.3390/cells12010022
|
| 9 |
Julie Thompson, Natasha Jones, Ali Al‐Khafaji, Shahid Malik, David Reich, Santiago Munoz, Ross MacNicholas, Tarek Hassanein, Lewis Teperman, Lance Stein, Andrés Duarte‐Rojo, Raza Malik, Talal Adhami, Sumeet Asrani, Nikunj Shah, Paul Gaglio, Anupama Duddempudi, Brian Borg, Rajiv Jalan, Robert Brown, Heather Patton, Rohit Satoskar, Simona Rossi, Amay Parikh, Ahmed ElSharkawy, Parvez Mantry, Linda Sher, David Wolf, Marquis Hart, Charles Landis, Alan Wigg, Shahid Habib, Geoffrey McCaughan, Steven Colquhoun, Alyssa Henry, Patricia Bedard, Lee Landeen, Michael Millis, Robert Ashley, William Frank, Andrew Henry, Jan Stange, Ram Subramanian. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. Liver Transplantation 2018; 24(3): 380 doi: 10.1002/lt.24986
|
| 10 |
Lijun Chen, Ning Zhang, Yuqi Huang, Qi Zhang, Yangxin Fang, Jiamin Fu, Yin Yuan, Lu Chen, Xin Chen, Zhenyu Xu, Yifei Li, Hiromi Izawa, Charlie Xiang. Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside. Stem Cell Reviews and Reports 2023; 19(7): 2192 doi: 10.1007/s12015-023-10583-5
|
| 11 |
Heng-Tong Han, Wei-Lin Jin, Xun Li. Mesenchymal stem cells-based therapy in liver diseases. Molecular Biomedicine 2022; 3(1) doi: 10.1186/s43556-022-00088-x
|
| 12 |
Miho Akabane, Yuki Imaoka, Jun Kawashima, Yutaka Endo, Austin Schenk, Kazunari Sasaki, Timothy M. Pawlik. Innovative Strategies for Liver Transplantation: The Role of Mesenchymal Stem Cells and Their Cell-Free Derivatives. Cells 2024; 13(19): 1604 doi: 10.3390/cells13191604
|
| 13 |
Yan-Wei Li, Chong Zhang, Qiu-Ju Sheng, Han Bai, Yang Ding, Xiao-Guang Dou. Mesenchymal stem cells rescue acute hepatic failure by polarizing M2 macrophages. World Journal of Gastroenterology 2017; 23(45): 7978-7988 doi: 10.3748/wjg.v23.i45.7978
|
| 14 |
Jinsol Han, Chanbin Lee, Hayeong Jeong, Seunghee Jeon, Myunggyo Lee, Haeseung Lee, Yung Hyun Choi, Youngmi Jung. Tumor necrosis factor-inducible gene 6 protein and its derived peptide ameliorate liver fibrosis by repressing CD44 activation in mice with alcohol-related liver disease. Journal of Biomedical Science 2024; 31(1) doi: 10.1186/s12929-024-01042-5
|